期刊
ACS APPLIED MATERIALS & INTERFACES
卷 11, 期 40, 页码 36371-36382出版社
AMER CHEMICAL SOC
DOI: 10.1021/acsami.9b11881
关键词
nanoparticles; drug delivery; chemoimmunotherapy; lipophilic prodrug; modular engineering; breast cancer
资金
- Sichuan Science and Technology Program [2019YJ0068]
- 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University [ZYYC08007, ZYJC18017]
- Science and Technology Project of Chengdu [2018-CY02-00041-GX]
Combination of chemotherapeutics and immunomodulators can generate synergistic anticancer efficacy, exerting efficient chemoimmunotherapy for cancer treatment. Nanoparticulate delivery systems hold great promise to promote synergistic anticancer efficacy for the codelivery of drugs. However, there remain challenges to precisely coencapsulate and deliver combinational drugs at designed ratios due to the difference of compatibility between drugs and nanocarriers. In this study, coassembled nanoparticles of lipophilic prodrugs (LPs) were designed to codeliver chemotherapeutics and immunomodulators for cancer treatment. Such nanoassemblies (NAs) could act as platforms to ratiometrically coencapsulate chemotherapeutics and immunomodulators. Based on this method, NAs formed by the self-assembly of iRGD peptide derivatives, paclitaxel (PTX) LPs, and imiquimod (R837) LPs were demonstrated to target the tumor at unified pharmacokinetics, further inducing the effective tumor inhibition and tumor recurrence prevention. This work provided an alternative to prepare chemoimmunotherapeutic NAs with advantages of ratiometric drug coencapsulation and unified pharmacokinetics, which may advance the future cancer chemoimmunotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据